Navigation Links
Successful human tests for first wirelessly controlled drug-delivery chip
Date:2/16/2012

(Cambridge, MA) About 15 years ago, MIT professors Robert Langer and Michael Cima had the idea to develop a programmable, wirelessly controlled microchip that would deliver drugs after implantation in a patient's body. This week, the MIT researchers and scientists from MicroCHIPS Inc. reported that they have successfully used such a chip to administer daily doses of an osteoporosis drug normally given by injection.

The results, published in the Feb. 16 online edition of Science Translational Medicine, represent the first successful test of such a device and could help usher in a new era of telemedicine delivering health care over a distance, Langer says.

"You could literally have a pharmacy on a chip," says Langer, the David H. Koch Institute Professor at MIT. "You can do remote control delivery, you can do pulsatile drug delivery, and you can deliver multiple drugs."

In the new study, funded and overseen by MicroCHIPS, scientists used the programmable implants to deliver an osteoporosis drug called teriparatide to seven women aged 65 to 70. The study found that the device delivered dosages comparable to injections, and there were no adverse side effects.

These programmable chips could dramatically change treatment not only for osteoporosis, but also for many other diseases, including cancer and multiple sclerosis. "Patients with chronic diseases, regular pain-management needs or other conditions that require frequent or daily injections could benefit from this technology," says Robert Farra, president and chief operating officer at MicroCHIPS and lead author of the paper.

"Compliance is very important in a lot of drug regimens, and it can be very difficult to get patients to accept a drug regimen where they have to give themselves injections," says Cima, the David H. Koch Professor of Engineering at MIT. "This avoids the compliance issue completely, and points to a future where you have fully automated dru
'/>"/>

Contact: Kimberly Allen
allenkc@mit.edu
617-253-2702
Massachusetts Institute of Technology
Source:Eurekalert

Page: 1 2 3

Related biology technology :

1. Spherics, Inc. Successful Bidder May Make NDA Submission
2. Spherics, Inc. Successful Bidder May Make MHRA Submission
3. CoreValve Successfully Treats the First Pacific Rim Patients with Its ReValving System for Percutaneous Aortic Valve Replacement : Australia/New Zealand Regulatory-Cleared Evaluation Registry is Expected to Lead to Market Clearance for These Countries
4. SAFC Hitech(TM) Successfully Demonstrates Device-Quality GST Precursors For Phase Change Memory Applications
5. Neptune Technologies successfully completes up to $8.5 million debt financing with Desjardins Group
6. ESBATech Announces Successful Completion of Phase I Clinical Study for Lead Antibody Fragment in Ophthalmic Indications
7. Small Animal Imaging Market: Biospace Lab Wins Frost & Sullivan Accolade for Its Successful Product Line Strategy
8. TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel
9. Neptune Technologies successfully completes $2.75 million private placement with 10% management participation
10. WeissComm Launches Invigorate Communications to Help Companies Build Successful Health-Based Brands
11. International Drug & Explosive Detection Firm Identa Corp Releasing: Jant Pharmacal Corporation Reports Successful Market Penetration of the Accutest(R) IDenta Co-brand in the United States and Oversees
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... famous for a number of breakthroughs, which altered the ... a paper, which laid the foundation of computer science, ... He next played a pivotal role in the Second ... military codes, enabling the Allies to defeat the Nazis ... he turned his attention to artificial intelligence and proposed ...
(Date:7/31/2014)... , July 31, 2014 The ... today with $25,000 to fund a translational research ... in 2011, the gift was presented at the ... Annual Meeting in Colorado Springs, CO. ... in neurointerventional approaches to neurovascular conditions, SNIS formed ...
(Date:7/31/2014)... North Shore Towers, a luxury co-op community based just ... of the nation’s leading combined heating and power (CHP) systems ... CHP system. The original CHP system had been maintained since ... life of the plant, GI Energy was contracted to replace ... equipment, while maintaining continuous operation of the entire complex. ...
(Date:7/31/2014)... DIEGO, July 31, 2014 Senomyx ... leading company using proprietary taste science technologies to ... the food, beverage, and ingredient supply industries, today ...  The Company ended the second quarter with $33.6 ... "During the past quarter Senomyx achieved ...
Breaking Biology Technology:A mathematical theory proposed by Alan Turing in 1952 can explain the formation of fingers 2A mathematical theory proposed by Alan Turing in 1952 can explain the formation of fingers 3SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 2SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 3North Shore Towers Partners with GI Energy to Install Turnkey Natural Gas-Fired Combined Heat and Power Plant 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 14SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 15SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 16
... Nov. 21, 2011 WaferGen Biosystems, Inc. (OTCBB:WGBS), an ... the three and nine months ended September 30, 2011 ... adoption of its SmartChip System. "During the ... strategy to address the rapidly changing needs of the ...
... Phase I Single Dose Study Data ... Convergence Pharmaceuticals Limited ("Convergence"), the company focused ... medicines, today announces that the multiple ascending dose Phase ... channel blocker CNV2197944, for the treatment of chronic pain ...
... Japan, November 18, 2011 - A research group from ... and Fujitsu Limited today announced that research results obtained ... Bell Prize, Peak-Performance at SC11, the International Conference for ... in Seattle, on November 17 (US Pacific Standard Time). ...
Cached Biology Technology:WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 2WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 3WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 4WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 5WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 6WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 7WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 8Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944 2Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944 3Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944 4'K computer' research results awarded ACM Gordon Bell Prize 2
(Date:8/1/2014)... Modern humans appear in the fossil record about 200,000 ... ago that making art and advanced tools became widespread. ... the journal Current Anthropology finds that human ... testosterone levels at around the same time that culture ... innovation, making art and rapid cultural exchange probably came ...
(Date:8/1/2014)... examining a taxonomically confused group of marine mammals ... the Australian humpback dolphin, Sousa sahulensis , ... Enterprises. , The study describing the newly ... long systematic examination of all available historical records, ... widespread group of coastal cetaceans ranging from the ...
(Date:8/1/2014)... key component of phloem, the conductive tissue through which ... molecules. Elongated cylindrical cells are capped at one end ... sieve tubes which in turn form a network throughout ... very special cells which play an important role in ... known about their differentiation," says Professor Yk Helariutta from ...
Breaking Biology News(10 mins):Society bloomed with gentler personalities and more feminine faces 2Scientists name new species of cetacean: The Australian humpback dolphin 2Scientists name new species of cetacean: The Australian humpback dolphin 3Developmental regulation of important plant phloem components discovered 2
... indicating that more than 50% of all osteoporotic hip fractures ... and treatment of osteoporotic fractures has become a major health ... Osteoporosis (IOF WCO), to be held for the first time ... the region to attend the leading global congress devoted to ...
... new drug trabectedin with pegylated liposomal doxorubicin provides clinical ... new results presented at the 33rd Congress of the ... The combination, which importantly does not include a ... women whose cancer recurs at least 6 months after ...
... N.C. A newly discovered chemical pathway that helps ... 20 common beta-blockers, drugs that are prescribed to millions ... Researchers from Duke University Medical Center tested 20 beta ... and carvedilol -- could stimulate a pathway recently found ...
Cached Biology News:IOF World Congress on Osteoporosis in Bangkok to address Asian issues 2Promising new treatment option for women with recurrent ovarian cancer 22 beta blockers found to also protect heart tissue 2
Collected from sexually mature, mixed sex, mixed breed guinea pigs. Pricing: $120/unit for 1 - 10 units...
SEQUENASE PCR PRODUCT PRE-SEQU, 1 EA. Category: SEQUENASE....
Mouse monoclonal [IFR0104] to Salmonella enteriditis ( Abpromise for all tested applications)....
All serum is collected from adult animals aged 6 months or older. Certified U.S. orgin. Pricing: $35/unit for 1 - 10 units...
Biology Products: